Ignite Creation Date:
2025-12-24 @ 9:24 PM
Ignite Modification Date:
2026-03-29 @ 3:05 AM
Study NCT ID:
NCT00992732
Status:
TERMINATED
Last Update Posted:
2011-08-01
First Post:
2009-10-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
Sponsor:
HemaQuest Pharmaceuticals Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
HQP-1004-EB-03
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Patrick Bobbitt, Vice President, Development
Old Organization:
HemaQuest Pharmaceuticals, Inc.